

CIRM Funded Clinical Trials

Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis

Disease Area:	Osteoarthritis
Investigator:	Kristen Johnson
Institution:	Calibr
CIRM Grant:	CLIN2-10388 (Closed)
Award Value:	\$8,447,523
Trial Sponsor:	Calibr
Trial Stage:	Phase 1
Trial Status:	Completed
Targeted Enrollment:	60
ClinicalTrials.gov ID:	NCT03133676



Kristen Johnson

Details:

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded \$8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease.

Design:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.

Goal:

This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.

Updates:

Podcast - Dr. Kristen Johnson & Dr. Maria Millan: Regenerative Medicine for Osteoarthritis

Contact Trial Sponsor